Ceritinib Targets Brain Metastases in Patients with ALK-positive NSCLC
Lung cancer and other thoracic tumours; Anticancer agents and biologic therapy; Personalised medicine
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1651 results
Secondary Resectability Improved with Induction Chemotherapy in Locally Advanced Pancreatic Cancer
More patients were able to undergo resection following induction chemotherapy
Nivolumab Challenges Sorafenib as First-line Treatment in Advanced HCC
Nivolumab improved response and showed trend towards improved survival compared to sorafenib in the first-line setting in patients with advanced hepatocellular carcinoma
EMA Recommends Granting the Marketing Authorisation for Generic Arsenic Trioxide
Arsenic trioxide Accord is intended for the treatment of acute promyelocytic leukaemia
EMA Recommends Granting a Marketing Authorisation for Generic Bortezomib
Bortezomib Fresenius Kabi is intended for the treatment of multiple myeloma and mantle cell lymphoma
EMA Recommends Extension of Indications for Avelumab
New indication concerns combination with axitinib for the first-line treatment of adults with advanced RCC
EMA Recommends Granting a Marketing Authorisation for Gilteritinib
It is indicated for the treatment of adult patients who have relapsed or refractory AML with a FLT3 mutation
FDA Approves Apalutamide for Metastatic Castration-Sensitive Prostate Cancer
Evidence for efficacy is based on the results from the TITAN trial
Simultaneous Review Decisions for Pembrolizumab Plus Lenvatinib in Australia, Canada and US
Combination treatment concerns patients with advanced endometrial carcinoma who progressed on prior systemic treatment and whose tumours are not MSI-H or dMMR
EMA Recommends Refusal of the Marketing Authorisation for Doxolipad
Doxolipad, a hybrid medicine, contains the active substance doxorubicin
Horizon Europe 2021-2027
The next research and innovation framework programme
In High- and Some Middle-Income Countries, Deaths From Cancer Are Now More Common Than Those From Cardiovascular Disease
PURE findings reflect transition in the predominant causes of deaths in middle-age